Ignite Creation Date:
2024-05-11 @ 8:30 AM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06402630
Status:
COMPLETED
Last Update Posted:
2024-05-07
First Post:
2024-04-26
Brief Title:
A Phase 2 Placebo Controlled Clinical Trial Designed to Assess the Efficacy Safety and Dose Response Characterisation of STS01 for the Treatment of Mild-moderate Alopecia Areata AA
Sponsor:
Soterios Ltd
Organization:
Soterios Ltd
Study Overview
Official Title:
A Phase 2 Double-blind Multicentre Placebo Controlled Parallel Group Design to Assess the Efficacy Safety and Dose Response Characterisation of STS01 for the Treatment of Mild-moderate Alopecia Areata AA
Status:
COMPLETED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SOT01
Brief Summary:
A Phase 2 double-blind multi-site placebo-controlled parallel-group design to assess the efficacy safety and dose-response characterisation of STS-01 for the treatment of mild- moderate alopecia areata
Detailed Description:
STS-01 is being developed to address the need for an effective safe and convenient non-steroidal topical treatment for mild-moderate alopecia areata The product builds on a mechanism with a well-established safety profile in dermatology and existing evidence of its effectiveness in this condition through targeting key relevant cytokines STS-01 has been modified to maximise the effectiveness of this mechanism and offer a cosmetically elegant topical cream The study aims to assess the effectiveness safety and dose-response characteristics of STS-01 for the treatment of mild-moderate alopecia areata
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2021-004145-20 | EUDRACT_NUMBER | None | None |